Med - a Cell Press journal
banner
cp-med.bsky.social
Med - a Cell Press journal
@cp-med.bsky.social
Med publishes transformative, evidence-based science across the clinical and translational research continuum—from large-scale clinical trials to translational studies with demonstrable functional impact. See our latest papers at https://www.cell.com/med
Online Now: Intestinal barrier alterations in mice following fecal microbiota transplant from children of IBD-affected mothers
Intestinal barrier alterations in mice following fecal microbiota transplant from children of IBD-affected mothers
Like their mothers, infants born to mothers with IBD show gut microbiome alterations. Transplantation of these microbiomes to mice causes metabolomic and gene expression changes consistent with a reduced barrier function.
dlvr.it
November 12, 2025 at 4:27 PM
Online Now: Semaglutide for the treatment of cognitive dysfunction in major depressive disorder: A randomized clinical trial
Semaglutide for the treatment of cognitive dysfunction in major depressive disorder: A randomized clinical trial
Cognitive impairment is a core feature of depression. Badulescu et al. tested the efficacy of oral semaglutide for the treatment of cognitive dysfunction in the first RCT conducted in patients with a mood disorder. They found that semaglutide was psychiatrically safe but not effective at improving executive function.
dlvr.it
November 11, 2025 at 7:59 PM
Online Now: Prostate cancer in situ autovaccination with the intratumoral viral mimic poly-ICLC: Modulating the cold tumor microenvironment
Prostate cancer in situ autovaccination with the intratumoral viral mimic poly-ICLC: Modulating the cold tumor microenvironment
In the first prostate cancer trial of intratumoral immunotherapy, sequential intratumoral and intramuscular poly-ICLC was safe and well tolerated in patients with intermediate- to high-risk localized disease. Treatment induced local and systemic immune activation and remodeled the tumor microenvironment, supporting further evaluation of this in situ autovaccination strategy.
dlvr.it
October 30, 2025 at 12:24 PM
Online Now: Tiered school-family-clinic intervention for childhood obesity prevention in China: A nested cluster randomized controlled trial
Tiered school-family-clinic intervention for childhood obesity prevention in China: A nested cluster randomized controlled trial
A tiered school-family-clinic intervention integrated with mobile health tools was deployed in Chinese primary schools and tailored to baseline weight. Over one school year, the program attenuated BMI gain, reduced obesity prevalence, and improved health behaviors, offering a scalable, low-cost model for broader public health adoption.
dlvr.it
October 29, 2025 at 3:27 PM
Online Now: TQB3617, a bromodomain and extra-terminal inhibitor, in patients with relapsed or refractory lymphoma: A multicenter, phase 1 trial
TQB3617, a bromodomain and extra-terminal inhibitor, in patients with relapsed or refractory lymphoma: A multicenter, phase 1 trial
Zhang et al. report on the dose-escalation phase 1 trial of the BET inhibitor TQB3617 in patients with relapsed or refractory lymphomas. TQB3617 demonstrates an acceptable safety profile and promising antitumor activity, warranting further investigation in a phase 2 trial.
dlvr.it
October 28, 2025 at 7:00 PM
Online Now: Strategy and clinical benefit of first re-resection for recurrent adult-type diffuse glioma: A retrospective cohort analysis
Strategy and clinical benefit of first re-resection for recurrent adult-type diffuse glioma: A retrospective cohort analysis
The optimal surgical strategy for recurrent adult-type diffuse glioma is controversial. This study finds that ideal surgical goals depend on the tumor’s molecular type, providing an evidence-based framework to guide personalized treatment and predict patient outcomes.
dlvr.it
October 25, 2025 at 6:59 PM
Online Now: Thirty years of intravenous thrombolysis for acute ischemic stroke: Historical perspectives, evidence from randomized trials, and emerging directions
Thirty years of intravenous thrombolysis for acute ischemic stroke: Historical perspectives, evidence from randomized trials, and emerging directions
This review highlights recent advances in the management of acute ischemic stroke with a focus on intravenous thrombolysis. It synthesizes pivotal clinical trials and emerging concepts, outlining current evidence and future directions in the quest to improve outcomes after ischemic stroke.
dlvr.it
October 23, 2025 at 12:24 PM
Online Now: Discrepant effect estimates in randomized clinical trials between high-income and low/middle-income countries: A meta-research study
Discrepant effect estimates in randomized clinical trials between high-income and low/middle-income countries: A meta-research study
Jia et al. analyze 1,005 randomized clinical trials and find that trials from low/middle-income countries report significantly larger treatment effects than those from high-income countries, especially for patient-reported outcomes. The discrepancies are smaller for trials with a low risk of bias, suggesting that bias might contribute to the discrepancies.
dlvr.it
October 22, 2025 at 3:27 PM
Online Now: Safety and tolerability of intrarectal perfluorodecalin for enteral ventilation in a first-in-human trial
Safety and tolerability of intrarectal perfluorodecalin for enteral ventilation in a first-in-human trial
This first-in-human, dose-escalation trial demonstrates that intrarectal administration of perfluorodecalin is safe and well tolerated in healthy volunteers, with no systemic absorption. These findings provide the foundational safety data to advance enteral ventilation as a novel therapeutic strategy for patients with respiratory failure.
dlvr.it
October 21, 2025 at 6:59 PM
Less than 3 weeks before scientists and clinicians convene in Los Angeles, CA for @CellSymposia #CSStemCells2025. Check out the scientific program and register today: http://dlvr.it/TNkn4K
October 17, 2025 at 3:51 PM
Online Now: Safety, tolerability, and pharmacokinetics of lisaftoclax (APG-2575)-based therapy in patients with chronic lymphocytic leukemia: Phase 1b/2 study
Safety, tolerability, and pharmacokinetics of lisaftoclax (APG-2575)-based therapy in patients with chronic lymphocytic leukemia: Phase 1b/2 study
Targeted therapies have transformed the CLL treatment landscape, but resistance and intolerance are challenges. Here, Davids and colleagues report a phase 1b/2 clinical trial showing that, with a 5- to 7-day ramp-up, lisaftoclax (with or without rituximab or acalabrutinib) was well tolerated and showed promising activity in patients with CLL.
dlvr.it
October 17, 2025 at 3:27 PM
Online Now: TQB2450 plus intensity-modulated radiotherapy in recurrent nasopharyngeal carcinoma: An open-label, single-arm, phase II trial
TQB2450 plus intensity-modulated radiotherapy in recurrent nasopharyngeal carcinoma: An open-label, single-arm, phase II trial
This study evaluates the efficacy and safety of TQB2450 plus IMRT in patients with rNPC and demonstrates that the combination exhibits promising antitumor activity with manageable toxicity. MIF expression, tumor microenvironment characteristics, TCR diversity, and serial plasma EBV DNA levels could identify patients who would benefit from this therapeutic strategy.
dlvr.it
October 8, 2025 at 3:27 PM
Online Now: Real-time diagnosis of cholangiocarcinoma by combining digestive endoscopy and optic fiber biosensors based on bile clusterin
Real-time diagnosis of cholangiocarcinoma by combining digestive endoscopy and optic fiber biosensors based on bile clusterin
Gao et al. have developed an optic fiber biosensor capable of detecting CLU protein in bile, which, integrated with digestive endoscopy, enables real-time in vivo diagnosis of cholangiocarcinoma. The technique has been thoroughly validated in pigs and patients, demonstrating exceptional diagnostic accuracy and rapid detection.
dlvr.it
September 11, 2025 at 12:24 PM